Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06189391 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06189391 · ClinicalTrials.gov record · last posted 2026-06-26

A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)

StatusRecruiting
PhasePhase 1
Started2021-03-16
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
Researchers are looking for new ways to treat people with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). B-cells are a type of white blood cells that make antibodies and help fight infections. Non-Hodgkin Lymphoma is a type of cancer in the lymphatic system causing enlarged lymph nodes and/or organs in belly or chest. Relapsed means a disease or condition comes back after treatment Refractory means a disease does not respond to treatment or stops responding to a treatment. MK-1045, the study medicine, is designed to treat relapsed or refractory B-NHL. MK-1045 is an immunotherapy, which is a treatment that helps the immune system fight cancer. This is the first study in which MK-1045 will be given to people. The goal of this study is to learn about: * The safety of MK-1045 and how well people tolerate it. * The highest dose of MK-1045 that is well tolerated. * How well MK-1045 works to treat relapsed or refractory B-NHL.

Amendment record 15 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 15 times since 2023-12-19; most recent amendment 2026-06-24. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

Trial Details
NCT Number NCT06189391
Lead Sponsor MSD R&D (China) Co., Ltd.
Conditions Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Enrollment 100 participants
Start Date 2021-03-16
Primary Completion 2028-09-30 (estimated)
Study Completion 2029-03-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-26